-
Signature
-
/s/ Judit Ryvkin, Attorney-in-Fact
-
Stock symbol
-
MIRM
-
Transactions as of
-
Dec 1, 2025
-
Transactions value $
-
-$3,553,200
-
Form type
-
4
-
Date filed
-
12/2/2025, 04:04 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| GREY MICHAEL G |
Director |
C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY |
/s/ Judit Ryvkin, Attorney-in-Fact |
2025-12-02 |
0001240122 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
MIRM |
Common Stock |
Options Exercise |
$147K |
+50K |
|
$2.94 |
50K |
Dec 1, 2025 |
Direct |
|
| transaction |
MIRM |
Common Stock |
Sale |
-$3.7M |
-50K |
-100% |
$74.00 |
0 |
Dec 1, 2025 |
Direct |
F1 |
| holding |
MIRM |
Common Stock |
|
|
|
|
|
186K |
Dec 1, 2025 |
By The Grey Family Trust dated November 12,1999 |
|
| holding |
MIRM |
Common Stock |
|
|
|
|
|
93.8K |
Dec 1, 2025 |
By The Grey 2018 Irrevocable Children's Trust |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
MIRM |
Stock Option (right to buy) |
Options Exercise |
$0 |
-50K |
-17.78% |
$0.00 |
231K |
Dec 1, 2025 |
Common Stock |
50K |
$2.94 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: